New award for ranibizumab (BYOOVIZ) vials with biogen U.S. Corporation. Period of performance is 12/23/23 to 12/22/24 with four one-year options.
Ended Indefinite Delivery Contract Awarded Last action
- Contract number
- 36E79724D0002
- Awardee
-
Biogen U.s. Corporation UEI E82LHNZSCUA3
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- 6505--Ranibizumab Pre-Solicitation · 36E79723R0018 · Posted Jun 15, 2023
- Last date to order 100% complete
- IDV ceiling
- $11,392,063.40
- Award type
- Single award
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
Biogen U.S. Corporation was awarded a single-award Indefinite Delivery Contract by the Veterans Affairs National Acquisition Center on December 23, 2023, for the supply of ranibizumab (BYOOVIZ) vials. The contract carries a ceiling value of $11.4 million and covers pharmaceutical supply to the Department of Veterans Affairs, Bureau of Prisons, and Indian Health Service. The initial period of performance ran from December 23, 2023, through December 22, 2024, with four one-year option periods available. No set-aside designation was used in the procurement, allowing Biogen to compete on an open-market basis. A bilateral modification was subsequently issued to exercise the first option year while declining the second option year, resulting in a contract completion date of December 22, 2025.
Ranibizumab is an ophthalmic anti-vascular endothelial growth factor injection used to treat age-related macular degeneration and other retinal conditions. Under this indefinite delivery vehicle structure, the government maintains the flexibility to issue delivery orders for the required pharmaceutical supply without establishing individual firm pricing through separate solicitations. This procurement approach enables efficient supply chain management for a critical ophthalmic therapeutic across multiple federal healthcare agencies, streamlining acquisition processes while ensuring consistent product availability for eligible patient populations served by the VA, correctional healthcare systems, and Indian Health Service facilities.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Add Subcontract Plan | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Add Subcontract Plan | $0 | |
| Add Subcontract Plan | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79724D0002?
36E79724D0002 was awarded to Biogen U.s. Corporation by National Acquisition Center (Headquarters) on December 23, 2023.
How much is contract 36E79724D0002 worth?
36E79724D0002's own ceiling is $11,392,063.
Who can order from contract 36E79724D0002?
36E79724D0002 is a single award indefinite delivery contract.
Was contract 36E79724D0002 competed?
The extent of competition for 36E79724D0002 was full and open competition. The government received 3 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV